Issue link: http://osercommunicationsgroup.uberflip.com/i/858133
Chain Drugstore Daily Tuesday, August 22, 2017 4 H. D. SMITH BUILDS VALUE WITH INTEGRATED APPROACH By Tom Doyle, Executive Vice President, H. D. Smith Specialty Solutions A holistic service provider such as H. D. Smith can create significant value for both existing and emerging pharmaceuti- cal companies. Most commercial teams have spent years developing a product and market for a successful launch, yet may lack either the internal resources or external partnerships to fully support commercialization. When seeking a strategic partnership, it is important to not only align with the capabilities of the partners, but to also ensure the culture and long-term objectives are focused on creating value across the supply chain. This approach is critical for emerg- ing pharmaceutical companies where it is often difficult to find a single provider with the ability to develop cus- tomized solutions for smaller product launches. A strategic supply chain part- ner will be able to provide key insights through years of experience and lever- age a wide range of solutions, includ- ing: freight-forwarding services to sup- port the movement of product from out- side the U.S.; full-line 3PL services including order-to-cash, charge- back and returns process- ing; distribution support ranging from traditional wholesale to limited net- works and other custom solutions by integrating 3PL, specialty distribution and in-house or pharmacy partners; title model programs; direct-to-practitioner and field sales sampling programs; white space coverage through direct engagement and fulfillment support services; patient assistance programs with direct-to-patient or site-of-care product delivery through the integration TAGI PHARMA ANNOUNCES FDA APPROVAL FOR 12.5MG AND 25MG TETRABENAZINE TABLETS TAGI Pharma, Inc., a specialty pharma- ceutical company and subsidiary of Precision Dose, Inc., announced FDA approval of the 12.5mg and 25mg Tetrabenazine Tablets ANDA in the United States and its territories, posses- sions and protectorates. 12.5mg and 25mg Tetrabenazine Tablets are a vesicular monoamine trans- porter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington's disease. Contraindications include patients who are actively suici- dal, or who have depression which is untreated or undertreated, hepatic impair- ment, and taking MAOIs or reserpine. Please visit www.tagipharma.com to view Tetrabenazine Tablets full prescrib- ing information which includes indica- tions for use, additional important safety information and boxed warning. Thomas Anderson, Executive President and responsible for TAGI's Business Development activities, said, "This approval represents an additional step forward in the implementation of TAGI Pharma's busi- ness plan to bring differentiated products to the marketplace, utilizing an aggres- sive business development initiative to license, acquire and co-develop prod- ucts." Kenny Harrington, Vice President of Sales and Marketing of TAGI Pharma, said "This approval ensures wider avail- ability to the market for Tetrabenazine Tablets and complements TAGI's strate- gy to provide unique products to under- served customers. Tetrabenazine has Continued on Page 61 Continued on Page 61 AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS Kimberly Oser Publisher Jules Denton Senior Associate Publisher Lorrie Baumann Editorial Director Jeanie Catron • JoEllen Lowry Associate Editors Yasmine Brown Art Director Jonathan Schieffer Graphic Designer Caitlyn McGrath • Sarah Glenn Customer Service Managers Stacy Davis • Jay Watson • Hannah Stefanovich Show Logistics & Distribution John Pechota Sales Floor Manager Marcos Morhaim Senior Account Manager Cami Jimenez • Frank Wood Account Managers Tara Neal Director of Operations Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2017 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy www.osercommunicationsgroup.com Lee M. Oser Founder